Table 2 Outcomes of novel regimens in relapsed or refractory PTCL from 2023 ASH Annual Meeting

Novel agent + SCT vs. Chemotherapy + SCT vs. Novel agent vs. Chemotherapy

Retrospective

184

AITL (28.3%), PTCL-NOS (21.2%), ATLL (8.5%), and ALCL (13%)

N/A

mEFS 16.0 m vs. 15.0 m vs.3.9 m vs. 4.1 m,

mOS 70.7 m vs. not reached vs. 23.3 m vs. 16.7 m

N/A

1698

[11]

Lenalidomide maintenance after salvage therapy

Phase II

58

AITL (39.7%), PTCL-NOS (25.9%)

N/A

1-y PFS 49%, mOS 34.1 m

Hematologic toxicities: Neutropenia, Thrombocytopenia;

Non-hematologic toxicities: Skin rash (40%), Nausea (35%), Diarrhea (20%)

3073

[12]

Chidamide + Azacitidine

Phase I

19

AITL (57.9%), PTCL-NOS (42.1%)

2

ORR 56.25%, DCR 75%, mPFS 6.45 m, mOS 17.5 m

Pain at the injection site (75.0%), Neutropenia (56.3%), Erythema at the injection site (50.0%), Nausea (43.8%), Thrombocytopenia (37.5%), Feeble (37.5%), Anemia (31.3%), Diarrhea (31.3%), Neutropenia with fever (25.0%)

3076

[13]

Chidamide + Parsaclisib

Phase Ib/II

11

N/A

2

CR 55.6%

Neutropenia (36.4%), Leukopenia (9.1%), Elevation of ALT/AST (9.1%), Diarrhea (9.1%)

3075

[14]